艾迪药业
(688488)
| 流通市值：62.19亿 | | | 总市值：62.19亿 |
| 流通股本：4.21亿 | | | 总股本：4.21亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 256,844,988.06 | 225,355,528.66 | 336,606,980.87 | 302,351,077.27 |
| 应收票据及应收账款 | 225,421,007.52 | 193,277,635.26 | 168,644,387.68 | 228,743,309.86 |
| 其中：应收票据 | 14,930,799.38 | 10,861,599.12 | 9,401,506.54 | 10,414,429.39 |
| 应收账款 | 210,490,208.14 | 182,416,036.14 | 159,242,881.14 | 218,328,880.47 |
| 应收款项融资 | 19,984,040.1 | 14,344,786.06 | 21,328,453.36 | 14,825,723.79 |
| 预付款项 | 26,998,262.58 | 29,104,522.52 | 25,239,639.6 | 17,704,024.64 |
| 其他应收款合计 | 2,297,390.27 | 3,856,097.53 | 3,932,433.36 | 3,704,269.67 |
| 存货 | 191,717,822 | 184,877,931.55 | 192,042,214.76 | 172,384,661.68 |
| 其他流动资产 | 8,226,527.48 | 5,815,032.46 | 3,853,337.28 | 5,132,019.12 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 876,983,377.4 | 872,380,942.77 | 932,086,666.96 | 930,616,453.73 |
| 非流动资产: | | | | |
| 长期股权投资 | 97,876,788.67 | 91,865,225.53 | 94,004,980.07 | 88,597,464.74 |
| 其他非流动金融资产 | 61,638,602.4 | 59,018,727 | 61,730,687.23 | 65,078,600 |
| 固定资产 | 427,682,144.55 | 433,130,118.34 | 424,202,267.1 | 432,550,840.92 |
| 在建工程 | 557,647.63 | 3,121,024.94 | 15,081,081.89 | 10,064,925.25 |
| 使用权资产 | 6,387,212.28 | 7,287,833.6 | 3,327,788.79 | 4,056,240.57 |
| 无形资产 | 111,833,432.51 | 114,591,396.42 | 116,929,838.9 | 119,584,097.1 |
| 开发支出 | 79,065,788.03 | 76,615,323.48 | 71,169,923.39 | 67,649,188.58 |
| 商誉 | 13,239,342.66 | 13,239,342.66 | 13,239,342.66 | 13,239,342.66 |
| 长期待摊费用 | 6,971,500.44 | 7,287,866.84 | 5,191,291.16 | 5,372,152.45 |
| 递延所得税资产 | 57,763,215.44 | 54,290,048.08 | 46,259,192.16 | 42,414,700.19 |
| 其他非流动资产 | 12,516,631.13 | 13,737,520.63 | 15,807,324.46 | 19,511,295.34 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 875,532,305.74 | 874,184,427.52 | 866,943,717.81 | 868,118,847.8 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,752,515,683.14 | 1,746,565,370.29 | 1,799,030,384.77 | 1,798,735,301.53 |
| 流动负债: | | | | |
| 短期借款 | 265,573,734.99 | 255,553,443.33 | 245,629,850.01 | 225,616,211.12 |
| 应付票据及应付账款 | 105,238,489.81 | 113,566,112.12 | 104,440,454.44 | 113,714,547.18 |
| 其中：应付票据 | 23,126,797.61 | 3,175,435.91 | 10,467,399 | 16,887,994 |
| 应付账款 | 82,111,692.2 | 110,390,676.21 | 93,973,055.44 | 96,826,553.18 |
| 合同负债 | 1,905,183.31 | 6,254,674.35 | 31,776,614.62 | 31,506,683.19 |
| 应付职工薪酬 | 8,486,876.06 | 16,902,636.91 | 7,963,482.82 | 7,858,022.8 |
| 应交税费 | 1,688,709.51 | 2,072,147.64 | 6,194,786.47 | 7,007,763.22 |
| 其他应付款合计 | 9,034,654.69 | 8,066,308.07 | 7,774,424.64 | 7,936,611.11 |
| 一年内到期的非流动负债 | 173,484,313.29 | 83,851,402.02 | 82,699,365.79 | 82,676,513.07 |
| 其他流动负债 | 3,652,255.42 | 5,301,258.4 | 3,569,851.72 | 4,775,473.97 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 569,064,217.08 | 491,567,982.84 | 490,048,830.51 | 481,091,825.66 |
| 非流动负债: | | | | |
| 长期借款 | 9,940,000 | 69,940,000 | 69,990,000 | 60,000,000 |
| 租赁负债 | 3,428,518.84 | 2,955,309.8 | 1,389,992.69 | 1,777,150.96 |
| 递延收益 | 49,786,193.27 | 50,285,406.26 | 52,333,196.59 | 53,684,709.53 |
| 递延所得税负债 | 6,474,799.56 | 6,278,458.48 | 6,452,781.77 | 7,179,206.64 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 69,629,511.67 | 129,459,174.54 | 130,165,971.05 | 122,641,067.13 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 638,693,728.75 | 621,027,157.38 | 620,214,801.56 | 603,732,892.79 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 420,782,808 | 420,782,808 | 420,782,808 | 420,000,000 |
| 资本公积 | 890,238,954.96 | 888,348,324.13 | 898,014,382.52 | 892,079,308.48 |
| 其他综合收益 | 549,789.4 | 549,789.4 | 549,789.4 | 596,197.82 |
| 盈余公积 | 9,307,578.93 | 9,307,578.93 | 9,307,578.93 | 9,307,578.93 |
| 未分配利润 | -207,057,176.9 | -193,450,287.55 | -149,838,975.64 | -126,980,676.49 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,113,821,954.39 | 1,125,538,212.91 | 1,178,815,583.21 | 1,195,002,408.74 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,113,821,954.39 | 1,125,538,212.91 | 1,178,815,583.21 | 1,195,002,408.74 |
| 负债和股东权益合计 | 1,752,515,683.14 | 1,746,565,370.29 | 1,799,030,384.77 | 1,798,735,301.53 |
| 公告日期 | 2024-04-26 | 2024-04-16 | 2023-10-28 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |